Literature DB >> 17046656

X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.

Milos D Ikonomovic1, Eric E Abrahamson, Barbara A Isanski, Manik L Debnath, Chester A Mathis, Steven T Dekosky, William E Klunk.   

Abstract

Postmortem pathological diagnosis and basic research investigations of neurodegenerative disorders rely on histochemical staining procedures developed specifically to visualize abnormal protein conformation. In Alzheimer's disease (AD), two major pathological hallmarks are required to confirm the clinical diagnosis. Both consist of abnormally aggregated proteins that share the structural and histological properties common to all amyloid deposits. Amyloid-beta peptide (Abeta) of extracellular senile plaques (SP) and hyperphosphorylated tau of intracellular neurofibrillary tangles (NFT) are assembled in the abnormal beta-pleated sheet (amyloid-like) structural conformation that can be visualized with histological staining procedures using Congo red or its derivatives. These histochemical dyes bind amyloid with high affinity and allow easy detection of amyloid structure in postmortem brain samples. This chapter focuses on the development and application of a histological protocol using the compound X-34, a highly fluorescent derivative of Congo red, for sensitive detection of pathological amyloid structures in histopathological investigations of postmortem brain tissue. This procedure provides a simple and effective method for detailed fluorescent visualization of the localization and distribution of the majority of currently known major histopathological structures in AD, including compact cored, neuritic, and diffuse-appearing SP, NFT, dystrophic neurites, neuropil threads, and cerebrovascular amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046656     DOI: 10.1016/S0076-6879(06)12009-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  31 in total

1.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

2.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

3.  Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Tolga Uz; Hari Manev; Steven T Dekosky
Journal:  J Histochem Cytochem       Date:  2008-08-04       Impact factor: 2.479

4.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

Review 5.  Modulation and detection of tau aggregation with small-molecule ligands.

Authors:  Edward Chang; Nicolette S Honson; Bhaswati Bandyopadhyay; Kristen E Funk; Jordan R Jensen; Sohee Kim; Swati Naphade; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

6.  Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrils.

Authors:  Sergey V Matveev; Stefan Kwiatkowski; Vitaliy M Sviripa; Robert C Fazio; David S Watt; Harry LeVine
Journal:  Bioorg Med Chem Lett       Date:  2014-10-06       Impact factor: 2.823

7.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

8.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

9.  Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.

Authors:  William E Klunk
Journal:  Arch Neurol       Date:  2008-10

Review 10.  The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation.

Authors:  William E Klunk; Chester A Mathis
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.